Repeated regression of pulmonary metastases from renal cell carcinoma after treatment using different interferon-alpha preparations.

A 49-year-old man with pulmonary metastasis from renal cell carcinoma (RCC) was treated with recombinant IFN-alpha2b (Intron A). A complete response was achieved within 4 months and thereafter persisted for 5 years until he developed another lung lesion. Interleukin-2 (Imunace) was administered without any response. Finally, he was treated by natural IFN-alpha (OIF). The pulmonary lesion achieved a partial response after 11 months of treatment. Because IFN-alpha preparations include different subtypes, changing the use of IFN-alpha preparations may thus be a potentially useful option for the successful immunotherapy of RCC.

[1]  M. Ikeda,et al.  In vitro Modification of Th1/Th2 Balance by Interferon-alpha Subtypes in Peripheral Blood Mononuclear Cells from Patients with Hepatitis B Virusinfection , 2003 .

[2]  G. Mickisch Rational selection of a control arm for randomised trials in metastatic renal cell carcinoma. , 2003, European urology.

[3]  M. Kurimoto,et al.  The anti-tumor activities of interferon (IFN)-α in chronic myelogenous leukaemia (CML)-derived cell lines depends on the IFN-α subtypes , 2002 .

[4]  S. Naito,et al.  [Cytokine therapy for metastatic renal cell carcinoma]. , 2002, Gan to kagaku ryoho. Cancer & chemotherapy.

[5]  M. Kurimoto,et al.  Characterization of the antitumor activities of IFN-alpha8 on renal cell carcinoma cells in vitro. , 2001, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[6]  M. Kurimoto,et al.  Analysis of the antiviral activities of natural IFN-alpha preparations and their subtype compositions. , 2001, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[7]  J. Hiscott,et al.  Selective DNA Binding and Association with the CREB Binding Protein Coactivator Contribute to Differential Activation of Alpha/Beta Interferon Genes by Interferon Regulatory Factors 3 and 7 , 2000, Molecular and Cellular Biology.

[8]  S. Bohlander,et al.  Nomenclature of the Human Interferon Genesa , 1994 .

[9]  H. Yamada,et al.  [A case of multiple lung metastases and cervical lymph node metastasis of renal cell carcinoma failing to respond to interferon-alpha (IFN-alpha) but markedly responding to interleukin-2 (IL-2)]. , 2004, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.

[10]  A. Horiguchi,et al.  [Advanced renal cell carcinoma showing a different response to two types of interferon-alpha]. , 2004, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.

[11]  M. Ikeda,et al.  In vitro effects of interferon-alpha subtypes on the Th1/Th2 balance in the peripheral blood mononuclear cells from patients with hepatitis C virus infection , 2004 .

[12]  M. Kurimoto,et al.  The anti-tumor activities of interferon (IFN)-alpha in chronic myelogenous leukaemia (CML)-derived cell lines depends on the IFN-alpha subtypes. , 2002, Cancer letters.

[13]  S. Bohlander,et al.  Nomenclature of the human interferon genes. , 1993, Journal of interferon research.